IL18 and non-small cell lung carcinoma: Zhou et al. (Zhou et al., 2020) [94], from the group of A.M. Ring in Yale (Yale School of Medicine, New Haven, CT, USA), postulated that IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy in NSCLC, colorectal cancer, and melanoma.